Chidamide combined with traditional chemotherapy for primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma: A case report

doi:10.12998/wjcc.v10.i4.1341

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 4

This Article

(200)

(175)

(0)

(19)

(2)

(3818)

(3)

Peer-Review Report of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Case Report

World J Clin Cases. Feb 6, 2022; 10(4): 1341-1348
Published online Feb 6, 2022. doi: 10.12998/wjcc.v10.i4.1341

Full Size Figure Download Figure

Figure 1 Photographs of skin lesions before treatment. Scattered blood blisters were observed throughout the body, with the most severe blood blisters on the trunk, consistent with the distribution of skin transverse striae.

Citation: He ZD, Yang HY, Zhou SS, Wang M, Mo QL, Huang FX, Peng ZG. Chidamide combined with traditional chemotherapy for primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma: A case report. World J Clin Cases 2022; 10(4): 1341-1348
URL: https://www.wjgnet.com/2307-8960/full/v10/i4/1341.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i4.1341

He ZD, Yang HY, Zhou SS, Wang M, Mo QL, Huang FX, Peng ZG. Chidamide combined with traditional chemotherapy for primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma: A case report. World J Clin Cases 2022; 10(4): 1341-1348 [PMID: 35211568 DOI: 10.12998/wjcc.v10.i4.1341]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.